| Host |
Mouse and Rabbit |
| Klon |
304-1A5 & 31-A5 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Normal or neoplastic breast tissue. |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
Mouse IgG1/κ /Rabbit IgG |
| Verdünnung |
Recombinant full-length protein |
| Lokalisation |
Cytoplasm |
Mammaglobin Cocktail
|
Zeta Corporation |
304-1A5 & 31-A5 |
0.5 ml |
Concentrate |
CE/IVD |
Z2011MRS |
-
|
| Host |
Mouse and Rabbit |
| Klon |
304-1A5 & 31-A5 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Normal or neoplastic breast tissue. |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
Mouse IgG1/κ /Rabbit IgG |
| Verdünnung |
Recombinant full-length protein |
| Lokalisation |
Cytoplasm |
Mammaglobin Cocktail
|
Zeta Corporation |
304-1A5 & 31-A5 |
0.1 ml |
Concentrate |
CE/IVD |
Z2011MRT |
-
|
| Host |
Rabbit |
| Klon |
SP177 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Prostate adenocarcinoma |
| Verdünnung |
1:100 |
| Isotyp |
Rabbit IgG |
| Verdünnung |
Synthetic peptide derived from the C-terminus of human MAP4K4 protein |
| Lokalisation |
Cytoplasm |
MAP4K4
|
Zytomed Systems GmbH |
SP177 |
0.5 ml |
Concentrate |
RUO |
514-4772 |
-
|
| Host |
Rabbit |
| Klon |
SP177 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Prostate adenocarcinoma |
| Verdünnung |
1:100 |
| Isotyp |
Rabbit IgG |
| Verdünnung |
Synthetic peptide derived from the C-terminus of human MAP4K4 protein |
| Lokalisation |
Cytoplasm |
MAP4K4
|
Zytomed Systems GmbH |
SP177 |
1 ml |
Concentrate |
RUO |
514-4774 |
-
|
| Host |
Mouse |
| Klon |
A103 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Melanoma |
| Verdünnung |
1:20 - 1:50 |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Cytoplasm |
MART-1 (Melan-A)
|
Diagnostic Biosystems |
A103 |
1 ml |
Concentrate |
CE/IVD |
MOB277 |
-
|
| Host |
Mouse |
| Klon |
A103 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Melanoma |
| Verdünnung |
1:20 - 1:50 |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Cytoplasm |
MART-1 (Melan-A)
|
Diagnostic Biosystems |
A103 |
0.1 ml |
Concentrate |
CE/IVD |
MOB277-01 |
-
|
| Host |
Mouse |
| Klon |
A103 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Melanoma |
| Verdünnung |
1:20 - 1:50 |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Cytoplasm |
MART-1 (Melan-A)
|
Diagnostic Biosystems |
A103 |
0.5 ml |
Concentrate |
CE/IVD |
MOB277-05 |
-
|
| Host |
Mouse |
| Klon |
A103 |
| Format |
Ready-to-use |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Melanoma |
| Verdünnung |
- |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Cytoplasm |
MART-1 (Melan-A)
|
Diagnostic Biosystems |
A103 |
6 ml |
Ready-to-use |
CE/IVD |
PDM153 |
-
|
| Host |
Mouse + Rabbit |
| Klon |
M2-7C10 + M2-9E3 + T311 + BC37 |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Melanoma |
| Verdünnung |
- |
| Isotyp |
IgG2b + IgG2a + IgG |
| Lokalisation |
Cytoplasm, nucleus (pHH3) |
MART-1 + Tyrosinase + pHH3
|
Biocare Medical |
M2-7C10 + M2-9E3 + T311 + BC37 |
6 ml |
Ready-to-use |
CE/IVD |
API3186DSAA |
-
|
| Host |
Mouse |
| Klon |
M2-7C10 + M2-9E3 + T311 + BC34 |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Melanoma |
| Verdünnung |
- |
| Isotyp |
IgG2b + IgG2a + IgG1 |
| Lokalisation |
Cytoplasm + nucleus |
MART-1 + Tyrosinase + SOX10
|
Biocare Medical |
M2-7C10 + M2-9E3 + T311 + BC34 |
6 ml |
Ready-to-use |
CE/IVD |
API3165AA |
-
|
| Host |
Mouse |
| Klon |
M2-9E3 + T311 + BC34 |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Melanoma |
| Verdünnung |
- |
| Isotyp |
IgG2b + IgG2a + IgG1 |
| Lokalisation |
Cytoplasm, cytoplasm, nucleus |
MART-1 + Tyrosinase + SOX10
|
Biocare Medical |
M2-9E3 + T311 + BC34 |
6 ml |
Ready-to-use |
CE/IVD |
AVI3216G |
-
|
| Host |
Mouse |
| Klon |
24B72D11.1 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Small cell lung cancer |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Nucleus |
MASH1
|
Biocare Medical |
24B72D11.1 |
0.1 ml |
Concentrate |
CE/IVD |
ACI3131A |
-
|
| Host |
Mouse |
| Klon |
24B72D11.1 |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Small cell lung cancer |
| Verdünnung |
- |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Nucleus |
MASH1
|
Biocare Medical |
24B72D11.1 |
6 ml |
Ready-to-use |
CE/IVD |
API3131AA |
-
|
| Host |
Mouse |
| Klon |
CC1 |
| Format |
Concentrate |
| Methode |
F, P, WB |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Cytoplasm |
Mast Cell Chymase
|
Diagnostic Biosystems |
CC1 |
1 ml |
Concentrate |
CE/IVD |
MOB346 |
-
|
| Host |
Mouse |
| Klon |
CC1 |
| Format |
Concentrate |
| Methode |
F, P, WB |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Cytoplasm |
Mast Cell Chymase
|
Diagnostic Biosystems |
CC1 |
0.1 ml |
Concentrate |
CE/IVD |
MOB346-01 |
-
|
| Host |
Mouse |
| Klon |
CC1 |
| Format |
Concentrate |
| Methode |
F, P, WB |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Cytoplasm |
Mast Cell Chymase
|
Diagnostic Biosystems |
CC1 |
0.5 ml |
Concentrate |
CE/IVD |
MOB346-05 |
-
|
| Host |
Mouse |
| Klon |
CC1 |
| Format |
Ready-to-use |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil |
| Verdünnung |
- |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Cytoplasm |
Mast Cell Chymase
|
Diagnostic Biosystems |
CC1 |
6 ml |
Ready-to-use |
CE/IVD |
PDM159 |
-
|
| Host |
Mouse |
| Klon |
AA1 |
| Format |
concentrate |
| Methode |
P |
| Positivkontrolle |
Endometrial Cancer |
| Verdünnung |
1:100 |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Cytoplasmic |
Mast Cell Tryptase
|
Biocare Medical |
AA1 |
0.1 ml |
concentrate |
RUO |
ACR3277A |
-
|
| Host |
Mouse |
| Klon |
AA1 |
| Format |
Concentrate |
| Methode |
F, P, WB |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Cytoplasm |
Mast Cell Tryptase
|
Diagnostic Biosystems |
AA1 |
1 ml |
Concentrate |
CE/IVD |
MOB347 |
-
|
| Host |
Mouse |
| Klon |
AA1 |
| Format |
Concentrate |
| Methode |
F, P, WB |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Cytoplasm |
Mast Cell Tryptase
|
Diagnostic Biosystems |
AA1 |
0.1 ml |
Concentrate |
CE/IVD |
MOB347-01 |
-
|
| Host |
Mouse |
| Klon |
AA1 |
| Format |
Concentrate |
| Methode |
F, P, WB |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Cytoplasm |
Mast Cell Tryptase
|
Diagnostic Biosystems |
AA1 |
0.5 ml |
Concentrate |
CE/IVD |
MOB347-05 |
-
|
| Host |
Mouse |
| Klon |
AA1 |
| Format |
Ready-to-use |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil |
| Verdünnung |
- |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Cytoplasm |
Mast Cell Tryptase
|
Diagnostic Biosystems |
AA1 |
6 ml |
Ready-to-use |
CE/IVD |
PDM160 |
-
|
| Host |
Mouse |
| Klon |
OTI8A11+UMAB146 |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil or normal cervix |
| Verdünnung |
- |
| Isotyp |
Mouse IgG2b+ Mouse IgG1 |
| Lokalisation |
Nuclear |
MCM2 + TOP2A
|
Biocare Medical |
OTI8A11+UMAB146 |
7 ml |
Ready-to-use |
RUO |
ALR3181G7 |
-
|
| Host |
Mouse |
| Klon |
OTI8A11+UMAB146 |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil or normal cervix |
| Verdünnung |
- |
| Isotyp |
Mouse IgG2b+ Mouse IgG1 |
| Lokalisation |
Cytoplasm and cell membrane |
MCM2 + TOP2A
|
Biocare Medical |
OTI8A11+UMAB146 |
6 ml |
Ready-to-use |
CE/IVD |
API3181AA |
-
|
| Host |
Mouse |
| Klon |
OTI8A11+UMAB146 |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil or normal cervix |
| Verdünnung |
- |
| Isotyp |
Mouse IgG2b+ Mouse IgG1 |
| Lokalisation |
Cytoplasm and cell membrane |
MCM2 + TOP2A
|
Biocare Medical |
OTI8A11+UMAB146 |
25 ml |
Ready-to-use |
CE/IVD |
API3181H |
-
|
| Host |
Mouse |
| Klon |
OTI8A11+UMAB146 |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil or normal cervix |
| Verdünnung |
- |
| Isotyp |
Mouse IgG2b+ Mouse IgG1 |
| Lokalisation |
Nuclear |
MCM2 + TOP2A
|
Biocare Medical |
OTI8A11+UMAB146 |
6 ml |
Ready-to-use |
RUO |
AVR3181G |
-
|
| Host |
Rabbit |
| Klon |
ZR258 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
sample known to contain MDM2 protein |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG |
| Verdünnung |
Recombinant human MDM2 protein fragment |
| Lokalisation |
Nucleus |
MDM2
|
Zeta Corporation |
ZR258 |
1 ml |
Concentrate |
RUO |
Z2572RL-R |
-
|
| Host |
Rabbit |
| Klon |
ZR258 |
| Format |
ready-to-use |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
sample known to contain MDM2 protein |
| Verdünnung |
- |
| Isotyp |
IgG |
| Verdünnung |
Recombinant human MDM2 protein fragment |
| Lokalisation |
Nucleus |
MDM2
|
Zeta Corporation |
ZR258 |
7 ml |
ready-to-use |
RUO |
Z2572RP-R |
-
|
| Host |
Rabbit |
| Klon |
ZR258 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
sample known to contain MDM2 protein |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG |
| Verdünnung |
Recombinant human MDM2 protein fragment |
| Lokalisation |
Nucleus |
MDM2
|
Zeta Corporation |
ZR258 |
0.5 ml |
Concentrate |
RUO |
Z2572RS-R |
-
|
| Host |
Rabbit |
| Klon |
ZR258 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
sample known to contain MDM2 protein |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG |
| Verdünnung |
Recombinant human MDM2 protein fragment |
| Lokalisation |
Nucleus |
MDM2
|
Zeta Corporation |
ZR258 |
0.1 ml |
Concentrate |
RUO |
Z2572RT-R |
-
|
| Host |
Mouse |
| Klon |
3G187 |
| Format |
Concentrate |
| Methode |
P, WB, IF |
| Vorbehandlung |
Citrate |
| Verdünnung |
1:100 - 1:500 |
| Isotyp |
Mouse IgG2b kappa |
| Verdünnung |
A synthetic peptide corresponding to the N-terminus of human MDM2rom human MDM2 protein |
| Lokalisation |
nuclear |
MDM2 (Murine Double Minute 2)
|
Zytomed Systems GmbH |
3G187 |
50 µg (0.1 ml) |
Concentrate |
RUO |
113-0230 |
-
|
| Host |
Mouse |
| Klon |
SMP14 |
| Format |
Purified |
| Methode |
F, P, IP |
| Vorbehandlung |
EDTA pH 8,0 oder pH 9,0 |
| Positivkontrolle |
Breast Carcinoma |
| Verdünnung |
1:200 - 1:500 (P) |
| Isotyp |
Mouse IgG1 |
| Verdünnung |
Synthetic peptide, CSRPSTSSRRRAISE, corresponding to amino acids 154-167 of human MDM2 |
MDM2 (Murine Double Minute 2)
|
Zytomed Systems GmbH |
SMP14 |
100 µg |
Purified |
RUO |
613-0099 |
-
|
| Host |
Mouse |
| Klon |
SMP14 |
| Format |
Purified |
| Methode |
F, P |
| Vorbehandlung |
EDTA pH 8,0 oder pH 9,0 |
| Positivkontrolle |
Breast Carcinoma |
| Verdünnung |
1:200 - 1:500 (P) |
| Isotyp |
Mouse IgG1 |
| Verdünnung |
Synthetic peptide, CSRPSTSSRRRAISE, corresponding to amino acids 154-167 of human MDM2 |
MDM2 (Murine Double Minute 2)
|
Zytomed Systems GmbH |
SMP14 |
20 µg |
Purified |
RUO |
613-0100 |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Purified |
| Methode |
EL, WB |
| Isotyp |
Rabbit IgG |
| Verdünnung |
Synthetic peptide corresponding to amino acids 177-195 of mouse mdm2 |
MDM2 (Murine Double Minute 2)
|
Zytomed Systems GmbH |
polyclonal |
50 µg |
Purified |
RUO |
613-0355 |
-
|
| Host |
Mouse |
| Klon |
SMP14 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Liposarcoma. |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Amino acids 154-167 of MDM2 of human origin |
| Lokalisation |
Nucleus |
MDM2 (Murine Double Minute 2)
|
Zeta Corporation |
SMP14 |
1 ml |
Concentrate |
CE/IVD |
Z2189ML |
-
|
| Host |
Mouse |
| Klon |
SMP14 |
| Format |
Ready-to-use |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Liposarcoma. |
| Verdünnung |
- |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Amino acids 154-167 of MDM2 of human origin |
| Lokalisation |
Nucleus |
MDM2 (Murine Double Minute 2)
|
Zeta Corporation |
SMP14 |
7 ml |
Ready-to-use |
CE/IVD |
Z2189MP |
-
|
| Host |
Mouse |
| Klon |
SMP14 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Liposarcoma. |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Amino acids 154-167 of MDM2 of human origin |
| Lokalisation |
Nucleus |
MDM2 (Murine Double Minute 2)
|
Zeta Corporation |
SMP14 |
0.5 ml |
Concentrate |
CE/IVD |
Z2189MS |
-
|
| Host |
Mouse |
| Klon |
SMP14 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Liposarcoma. |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Amino acids 154-167 of MDM2 of human origin |
| Lokalisation |
Nucleus |
MDM2 (Murine Double Minute 2)
|
Zeta Corporation |
SMP14 |
0.1 ml |
Concentrate |
CE/IVD |
Z2189MT |
-
|
| Host |
Mouse |
| Klon |
A103 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Diva modified Citrate pH 6.2 |
| Positivkontrolle |
Melanoma |
| Verdünnung |
1:25 - 1:50 |
| Isotyp |
Rabbit IgG |
| Lokalisation |
Cytoplasmic |
Melan A
|
Biocare Medical |
A103 |
0.1 ml |
Concentrate |
CE/IVD |
ACI3114A |
-
|
| Host |
Mouse |
| Klon |
A103 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Diva modified Citrate pH 6.2 |
| Positivkontrolle |
Melanoma |
| Verdünnung |
1:25 - 1:50 |
| Isotyp |
Rabbit IgG |
| Lokalisation |
Cytoplasmic |
Melan A
|
Biocare Medical |
A103 |
0.5 ml |
Concentrate |
CE/IVD |
ACI3114B |
-
|
| Host |
Mouse |
| Klon |
A103 |
| Format |
Ready-to-use |
| Methode |
P |
| Positivkontrolle |
Melanoma |
| Verdünnung |
- |
| Isotyp |
Rabbit IgG |
| Lokalisation |
Cytoplasmic |
Melan A
|
Biocare Medical |
A103 |
7 ml |
Ready-to-use |
CE/IVD |
ALI3114G7 |
-
|
| Host |
Mouse |
| Klon |
A103 |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
Diva modified Citrate pH 6.2 |
| Positivkontrolle |
Melanoma |
| Verdünnung |
- |
| Isotyp |
Rabbit IgG |
| Lokalisation |
Cytoplasmic |
Melan A
|
Biocare Medical |
A103 |
6 ml |
Ready-to-use |
CE/IVD |
API3114AA |
-
|
| Host |
Mouse |
| Klon |
A103 |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
CC1 |
| Positivkontrolle |
Melanoma |
| Verdünnung |
- |
| Isotyp |
Rabbit IgG |
| Lokalisation |
Cytoplasmic |
Melan A
|
Biocare Medical |
A103 |
6 ml |
Ready-to-use |
CE/IVD |
AVI3114G |
-
|
| Host |
Mouse |
| Klon |
A103 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Skin or melanoma. |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Recombinant MART-1 protein |
| Lokalisation |
Cytoplasm |
Melan-A (MART-1)
|
Zeta Corporation |
A103 |
1.0 ml |
Concentrate |
CE/IVD |
Z2052ML |
-
|
| Host |
Mouse |
| Klon |
A103 |
| Format |
Ready-to-use |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Skin or melanoma. |
| Verdünnung |
- |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Recombinant MART-1 protein |
| Lokalisation |
Cytoplasm |
Melan-A (MART-1)
|
Zeta Corporation |
A103 |
7 ml |
Ready-to-use |
CE/IVD |
Z2052MP |
-
|
| Host |
Mouse |
| Klon |
A103 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Skin or melanoma. |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Recombinant MART-1 protein |
| Lokalisation |
Cytoplasm |
Melan-A (MART-1)
|
Zeta Corporation |
A103 |
0.5 ml |
Concentrate |
CE/IVD |
Z2052MS |
-
|
| Host |
Mouse |
| Klon |
A103 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Skin or melanoma. |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Recombinant MART-1 protein |
| Lokalisation |
Cytoplasm |
Melan-A (MART-1)
|
Zeta Corporation |
A103 |
0.1 ml |
Concentrate |
CE/IVD |
Z2052MT |
-
|
| Host |
Mouse |
| Klon |
PNL2 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Melanoma |
| Verdünnung |
1:10 - 1:25 |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Cytoplasm, Cell Membrane |
Melanoma
|
Diagnostic Biosystems |
PNL2 |
1 ml |
Concentrate |
CE/IVD |
MOB421 |
-
|
| Host |
Mouse |
| Klon |
PNL2 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Melanoma |
| Verdünnung |
1:10 - 1:25 |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Cytoplasm, Cell Membrane |
Melanoma
|
Diagnostic Biosystems |
PNL2 |
0.1 ml |
Concentrate |
CE/IVD |
MOB421-01 |
-
|
| Host |
Mouse |
| Klon |
PNL2 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Melanoma |
| Verdünnung |
1:10 - 1:25 |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Cytoplasm, Cell Membrane |
Melanoma
|
Diagnostic Biosystems |
PNL2 |
0.5 ml |
Concentrate |
CE/IVD |
MOB421-05 |
-
|